Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects
Critchley, David John, PhD, Aluri, Jagadeesh, MS, Boyd, Peter, MSc, Whayman, Matthew, MSc, Narurkar, Milind, PhD, Delargy, Hugh, PhD, Bibbiani, Francesco, MD
Published in Clinical therapeutics (2011)
Published in Clinical therapeutics (2011)
Get full text
Journal Article